Effective systemic blockade of endogenous nitric oxide production results in moderate hypertension, reduced sympathetic activity and shortened bleeding time in healthy volunteers.
Albert
J
J
Karolinska Institute, Danderyd Hospital, Division of Anesthesiology and Intensive Care, Sweden.
D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005221:Fatigue / Q000139:chemically induced; D005542:Forearm / Q000098:blood supply; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000209:etiology*; D007262:Infusions, Intravenous; D017116:Low Back Pain / Q000139:chemically induced; D008297:Male; D009569:Nitric Oxide / Q000037:antagonists & inhibitors*; D010100:Oxygen / Q000097:blood; D011651:Pulmonary Artery; D012039:Regional Blood Flow / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014655:Vascular Resistance / Q000187:drug effects; D019323:omega-N-Methylarginine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D010100:Oxygen